CLINICAL ASPECTS OF LOCAL AND REGIONAL TUMOR-THERAPY WITH RE-188-RC-160

Somatostatin-receptors have been found to be overexpressed in a variet y of neuroendocrine and epithelial cancers. While the introduction of a long-acting somatostatin-analogue octreotide, exerted mainly anti-ca ncer activity in neuro-endocrine tumors, no convincing results have be en demonstrated in other cancers. RC-160, another somatostin-analogue has been selected because of its high receptor affinity and its anti-c ancer. activity Re-188 is a generator produced radionuclide with favou rable gamma and beta-emission allowing diagnostic and therapeutic appl ication. The results of in vivo biodistribution and therapeutic outcom e following systemic, intralesional and intracavitary application in a nimal studies employing Re-188-RC-160 are summarized. Safety considera tions, dosimetry estimats and applicable indications are outlined The clinical impacts of this radiopharmaceutical in cancer management are discussed.